Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61


Hypergammaglobulinemic Purpura of Waldenstrom (HGPW) in Pregnancy: A Rare Case Report.

Malik R, Goyal A, Ganju V, Sardana K.

J Obstet Gynaecol India. 2019 Apr;69(Suppl 1):24-27. doi: 10.1007/s13224-018-1144-2. Epub 2018 Jun 12. No abstract available.


Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.

Leong TL, Gayevskiy V, Steinfort DP, De Massy MR, Gonzalez-Rajal A, Marini KD, Stone E, Chin V, Havryk A, Plit M, Irving LB, Jennings BR, McCloy RA, Jayasekara WSN, Alamgeer M, Boolell V, Field A, Russell PA, Kumar B, Gough DJ, Szczepny A, Ganju V, Rossello FJ, Cain JE, Papenfuss AT, Asselin-Labat ML, Cowley MJ, Watkins DN.

Oncogene. 2019 Mar;38(10):1661-1675. doi: 10.1038/s41388-018-0536-1. Epub 2018 Oct 22.


Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.

Marini KD, Croucher DR, McCloy RA, Vaghjiani V, Gonzalez-Rajal A, Hastings JF, Chin V, Szczepny A, Kostyrko K, Marquez C, Jayasekara WSN, Alamgeer M, Boolell V, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, de Kretser DM, Wu J, Ganju V, Sweet-Cordero EA, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Watkins DN.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaat3504. doi: 10.1126/scitranslmed.aat3504.


Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J.

Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.


A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.

Alamgeer M, Neil Watkins D, Banakh I, Kumar B, Gough DJ, Markman B, Ganju V.

Invest New Drugs. 2018 Apr;36(2):288-298. doi: 10.1007/s10637-017-0555-8. Epub 2017 Dec 26.


The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer.

Szczepny A, Rogers S, Jayasekara WSN, Park K, McCloy RA, Cochrane CR, Ganju V, Cooper WA, Sage J, Peacock CD, Cain JE, Burgess A, Watkins DN.

Oncogene. 2017 Sep 28;36(39):5544-5550. doi: 10.1038/onc.2017.173. Epub 2017 Jun 5.


Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengeløv L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W.

J Clin Oncol. 2017 Jan;35(1):40-47. Epub 2016 Oct 31.


Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C.

PLoS Med. 2016 Dec 6;13(12):e1002136. doi: 10.1371/journal.pmed.1002136. eCollection 2016 Dec.


A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer.

Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, King D, Strickland A, Franco M, Blum R, Johnson C, Ganju V, Shapiro J, Chong G, Charlton J, Haydon A, Schofield P.

Oncologist. 2016 Aug;21(8):1014-23. doi: 10.1634/theoncologist.2015-0533. Epub 2016 Jun 15.


Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P.

Lancet Oncol. 2016 Jun;17(6):811-821. doi: 10.1016/S1470-2045(16)00106-6. Epub 2016 May 4.


SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodríguez J, Kröning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P.

J Clin Oncol. 2016 May 20;34(15):1723-31. doi: 10.1200/JCO.2015.66.1181. Epub 2016 Feb 22. Erratum in: J Clin Oncol. 2016 Nov 20;34(33):4059.


Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V.

Br J Cancer. 2016 Mar 1;114(5):505-9. doi: 10.1038/bjc.2015.440. Epub 2016 Feb 11.


The Evolution of Therapies in Non-Small Cell Lung Cancer.

Boolell V, Alamgeer M, Watkins DN, Ganju V.

Cancers (Basel). 2015 Sep 9;7(3):1815-46. doi: 10.3390/cancers7030864. Review.


Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.

Ng SP, David S, Alamgeer M, Ganju V.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):111-7. doi: 10.1016/j.ijrobp.2015.05.012. Epub 2015 May 15.


Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD.

Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12.


Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens.

Leong TL, Marini KD, Rossello FJ, Jayasekara SN, Russell PA, Prodanovic Z, Kumar B, Ganju V, Alamgeer M, Irving LB, Steinfort DP, Peacock CD, Cain JE, Szczepny A, Watkins DN.

PLoS One. 2014 Sep 5;9(9):e106862. doi: 10.1371/journal.pone.0106862. eCollection 2014.


Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.

Alamgeer M, Ganju V, Kumar B, Fox J, Hart S, White M, Harris M, Stuckey J, Prodanovic Z, Schneider-Kolsky ME, Watkins DN.

Breast Cancer Res. 2014 Apr 24;16(2):R44. doi: 10.1186/bcr3648.


The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.

Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M, Conron M, Wright G, Watkins DN.

Thorax. 2013 Dec;68(12):1095-104. doi: 10.1136/thoraxjnl-2012-203021. Epub 2013 Jul 22.


Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, Espie M, Majois F, Gil MG, Vaissiere N, Villanova G.

Anticancer Res. 2013 Jun;33(6):2657-64.


Grand challenges: Integrating mental health care into the non-communicable disease agenda.

Ngo VK, Rubinstein A, Ganju V, Kanellis P, Loza N, Rabadan-Diehl C, Daar AS.

PLoS Med. 2013;10(5):e1001443. doi: 10.1371/journal.pmed.1001443. Epub 2013 May 14. No abstract available.


Novel therapeutic targets in non-small cell lung cancer.

Alamgeer M, Ganju V, Watkins DN.

Curr Opin Pharmacol. 2013 Jun;13(3):394-401. doi: 10.1016/j.coph.2013.03.010. Epub 2013 Apr 20. Review.


Cancer stem cells in lung cancer: Evidence and controversies.

Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN.

Respirology. 2013 Jul;18(5):757-64. doi: 10.1111/resp.12094. Review.


Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.

Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ; Australasian Gastro-Intestinal Trials Group (AGITG).

Br J Cancer. 2013 Mar 5;108(4):771-4. doi: 10.1038/bjc.2013.41. Epub 2013 Feb 14.


A United Nations General Assembly Special Session for mental, neurological, and substance use disorders: the time has come.

Bass JK, Bornemann TH, Burkey M, Chehil S, Chen L, Copeland JR, Eaton WW, Ganju V, Hayward E, Hock RS, Kidwai R, Kolappa K, Lee PT, Minas H, Or F, Raviola GJ, Saraceno B, Patel V.

PLoS Med. 2012 Jan;9(1):e1001159. doi: 10.1371/journal.pmed.1001159. Epub 2012 Jan 17. Review.


Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC.

Ann Oncol. 2012 Jun;23(6):1531-6. doi: 10.1093/annonc/mdr488. Epub 2011 Oct 29.


A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.

Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M.

J Thorac Oncol. 2011 Nov;6(11):1907-14. doi: 10.1097/JTO.0b013e318226b5fa.


The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.

Schneider-Kolsky ME, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, Ganju V.

Breast Cancer Res. 2010;12(3):R37. doi: 10.1186/bcr2591. Epub 2010 Jun 21.


Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ.

J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723. Epub 2010 Jun 1.


Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.

Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, Underhill CR, Fox RM, Clavant SP, Leung J, Pho M, Brown TJ.

Cancer Chemother Pharmacol. 2011 Jan;67(1):153-63. doi: 10.1007/s00280-010-1303-3. Epub 2010 Mar 24.


Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2010 Feb 2;102(3):475-81. doi: 10.1038/sj.bjc.6605522. Epub 2010 Jan 12.


Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting.

Sewak S, Kosmider S, Ganju V, Woollett A, Yeow EG, Le B, Henry M, Debrincat MA, Bell R.

Intern Med J. 2010 Mar;40(3):201-8. doi: 10.1111/j.1445-5994.2009.01987.x. Epub 2009 May 21.


The State Health Authority Yardstick (SHAY).

Finnerty MT, Rapp CA, Bond GR, Lynde DW, Ganju V, Goldman HH.

Community Ment Health J. 2009 Jun;45(3):228-36. doi: 10.1007/s10597-009-9181-z. Epub 2009 Mar 21.


A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.

Michael M, Price T, Ngan SY, Ganju V, Strickland AH, Muller A, Khamly K, Milner AD, Dilulio J, Matera A, Zalcberg JR, Leong T.

Br J Cancer. 2009 Jan 13;100(1):37-43. doi: 10.1038/sj.bjc.6604827. Epub 2008 Dec 16.


Mental health transformation: moving toward a public health, early-intervention approach in Texas.

Ganju V.

Psychiatr Serv. 2008 Jan;59(1):17-20. doi: 10.1176/ps.2008.59.1.17.


Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.

J Clin Oncol. 2007 Oct 20;25(30):4779-86.


The role of state mental health authorities in managing change for the implementation of evidence-based practices.

Isett KR, Burnam MA, Coleman-Beattie B, Hyde PS, Morrissey JP, Magnabosco JL, Rapp C, Ganju V, Goldman HH.

Community Ment Health J. 2008 Jun;44(3):195-211. Epub 2007 Oct 9.


The state policy context of implementation issues for evidence-based practices in mental health.

Isett KR, Burnam MA, Coleman-Beattie B, Hyde PS, Morrissey JP, Magnabosco J, Rapp CA, Ganju V, Goldman HH.

Psychiatr Serv. 2007 Jul;58(7):914-21.


PET positive progressive transformation of germinal centers masquerading as relapsed Hodgkin lymphoma post-autograft.

Grigg A, Ganju V.

Leuk Lymphoma. 2006 Apr;47(4):764-5. No abstract available.


A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R.

Clin Cancer Res. 2005 Aug 1;11(15):5504-14.


Effective treatment of leptomeningeal multiple myeloma with total craniospinal irradiation supported by second allogeneic donor stem cell infusion.

Quach H, Ryan G, Ganju V, Prince HM.

Bone Marrow Transplant. 2005 Feb;35(4):423-4. No abstract available.


Evidence-based practices: setting the context and responding to concerns.

Essock SM, Goldman HH, Van Tosh L, Anthony WA, Appell CR, Bond GR, Dixon LB, Dunakin LK, Ganju V, Gorman PG, Ralph RO, Rapp CA, Teague GB, Drake RE.

Psychiatr Clin North Am. 2003 Dec;26(4):919-38, ix. Review.


Educational best practices.

Stuart GW, Burland J, Ganju V, Levounis P, Kiosk S.

Adm Policy Ment Health. 2002 May;29(4-5):325-33.


Policy implications for implementing evidence-based practices.

Goldman HH, Ganju V, Drake RE, Gorman P, Hogan M, Hyde PS, Morgan O.

Psychiatr Serv. 2001 Dec;52(12):1591-7.


The mental health system in India. History, current system, and prospects.

Ganju V.

Int J Law Psychiatry. 2000 May-Aug;23(3-4):393-402. No abstract available.


A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

Rischin D, Webster LK, Millward MJ, Toner GC, Nawaratne S, Ganju V, Francis P, Bishop JF.

Invest New Drugs. 1999;17(1):73-80.


From consumer satisfaction to consumer perception of care.

Ganju V.

Behav Healthc Tomorrow. 1998 Aug;7(4):17-8. No abstract available.


A data platform for the consumer-oriented report card.

Manderscheid RW, Ganju V, Johnson JR, Henderson MJ.

Behav Healthc Tomorrow. 1997 Dec;6(6):18-9. No abstract available.


Supplemental Content

Support Center